FDA
-
-
-
-
-
-
-
SCIENTURE adds REZENOPY nasal spray to major health plan formulary
-
-
-
-
-
-
-
Scienture secures $11 million in non-dilutive debt financing
-
-
-
-
-
-
-
Scienture reports 216% revenue increase with FDA-approved drug launch
-
-
-
-
-
-
-
SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium
-
-
-
-
-
-
-
SCIENTURE Reports Q3 2025 Financial Results and Provides Business Update
-
-
-
-
-
-
-
SCIENTURE Secures PBM-Led GPO Rebate Agreement to Drive Expanded Commercial Coverage and Formulary Access for Arbli™(losartan potassium) in the $256M U.S. Losartan Market
-
-
-
-
-
-
-
Scienture Holdings (SCNX) Issues Annual Letter to Shareholders
-
328,282 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

